Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.07 USD
+0.05 (4.90%)
Updated May 9, 2024 04:00 PM ET
After-Market: $1.06 -0.01 (-0.93%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 301 - 320 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Get Carried Away With Karyopharm; Assuming Coverage With Buy Rating and $23 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
STOMP Update Supports Potential of Selinexor as Future Backbone in MM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Licensing Deal Brings Non-Dilutive Capital, Shares Look Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Sel Meets PFS Endpoint in Liposarcoma with Encouraging Safety Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - ESMO ''17 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Multiple Value Inflection Milestones Up Ahead for Selinexor, Ticking PT to $16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of Aug 7
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - The Week Ahead in Life Sciences: Upcoming Events for the Week of July 10
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Mid-''17 Sel Data in Solid Tumors; Blood Cancer Filings Possible in 2018
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Several Data Catalysts in Next 18 Mo, with Runway Potential to First Product Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D